All In Biotech

NDA 208558 · Astrazeneca

Lynparza

Olaparib · Oral · Poly(ADP-Ribose) Polymerase Inhibitor

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 17, 2017

Approved uses

15

Original approval plus efficacy supplements

Registered trials

455

49 Phase 3, 83 recruiting

FAERS reports

21,443

19,511 serious, 6,079 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 10, 2025.

Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with...

Mechanism: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA1/2 , ATM , or other genes...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 6, 2023 Supplement 28 · Efficacy OrphanLetterLabel
  • May 31, 2023 Supplement 25 · Efficacy · priority review LabelLetterReview
  • Aug 26, 2022 Supplement 26 · Efficacy · priority review OrphanLetterLabel
  • Mar 11, 2022 Supplement 23 · Efficacy · priority review LabelLetter
  • Jan 31, 2022 Supplement 21 · Efficacy OrphanLetterLabel
  • Mar 11, 2021 Supplement 19 · Efficacy OrphanLetterLabel
  • Dec 7, 2020 Supplement 16 · Efficacy · priority review LetterLabel
  • May 19, 2020 Supplement 14 · Efficacy · priority review LabelLetter
  • May 8, 2020 Supplement 13 · Efficacy · priority review OrphanLabelLetter
  • Dec 27, 2019 Supplement 10 · Efficacy · priority review OrphanLetterLabel
  • Jul 1, 2019 Supplement 9 · Efficacy LetterLabel
  • Dec 19, 2018 Supplement 6 · Efficacy · priority review OrphanLabelLetter
  • Sep 26, 2018 Supplement 5 · Efficacy LabelLetter
  • Jan 12, 2018 Supplement 1 · Efficacy · priority review LabelLetter
  • Aug 17, 2017 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetterReview
2 products under this application
  • LYNPARZA · OLAPARIB 150MG · TABLET, ORAL · Prescription
  • LYNPARZA · OLAPARIB 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olaparib" as an intervention, any sponsor and status, largest first.

All 455 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death4,833
  • malignant neoplasm progression2,129
  • nausea1,903
  • fatigue1,836
  • anaemia1,670
  • off label use971
  • vomiting761
  • neuropathy peripheral709
  • drug ineffective689
  • asthenia650
  • diarrhoea638
  • decreased appetite565

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20126
20131
20146
2015372
2016506
2017649
2018851
20191,426
20202,047
20212,215
20222,367
20232,863
20243,375
20252,747
20262,011

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lynparza (Olaparib)

2024 spending

$594M

Beneficiaries

7,016

41,444 claims

Per beneficiary

$84,654

$136.25 per unit

View as table
YearSpending
2020$358,856,238
2021$426,649,225
2022$460,720,287
2023$487,431,793
2024$593,929,898

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 413 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.